Abstract
We studied the effect of LHRH agonist administration on serum PRL levels in five women with microprolactinomas and two women and a man with intrasellar macroprolactinomas. Each patient received either D-Trp6-LHRH or buserelin for 90 days. Serum PRL levels decreased significantly in the patients with microprolactinomas by 65%, from 156 ± 93 (± SD) to 54 ± 49 μg/L on day 90 (P = 0.011), but it did not decrease in the macroprolactinoma patients. Mean serum LH and FSH decreased by 43% and 62.5%, respectively, in all eight patients. There was no statistically significant correlation between the serum PRL and LH or FSH levels in the microprolactinoma patients. We conclude that LHRH agonists can counteract the hyperprolactinemia produced by microprolactinomas and that the effect probably is not exerted by an action on the gonadotrophs.
| Original language | English |
|---|---|
| Pages (from-to) | 444-447 |
| Number of pages | 4 |
| Journal | Journal of Clinical Endocrinology and Metabolism |
| Volume | 69 |
| Issue number | 2 |
| State | Published - Jan 1 1989 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Endocrinology, Diabetes and Metabolism
Cite this
Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients. / Rubio, M. A.; Cabranes, J. A.; Schally, Andrew V; Charro, A. L.
In: Journal of Clinical Endocrinology and Metabolism, Vol. 69, No. 2, 01.01.1989, p. 444-447.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients
AU - Rubio, M. A.
AU - Cabranes, J. A.
AU - Schally, Andrew V
AU - Charro, A. L.
PY - 1989/1/1
Y1 - 1989/1/1
N2 - We studied the effect of LHRH agonist administration on serum PRL levels in five women with microprolactinomas and two women and a man with intrasellar macroprolactinomas. Each patient received either D-Trp6-LHRH or buserelin for 90 days. Serum PRL levels decreased significantly in the patients with microprolactinomas by 65%, from 156 ± 93 (± SD) to 54 ± 49 μg/L on day 90 (P = 0.011), but it did not decrease in the macroprolactinoma patients. Mean serum LH and FSH decreased by 43% and 62.5%, respectively, in all eight patients. There was no statistically significant correlation between the serum PRL and LH or FSH levels in the microprolactinoma patients. We conclude that LHRH agonists can counteract the hyperprolactinemia produced by microprolactinomas and that the effect probably is not exerted by an action on the gonadotrophs.
AB - We studied the effect of LHRH agonist administration on serum PRL levels in five women with microprolactinomas and two women and a man with intrasellar macroprolactinomas. Each patient received either D-Trp6-LHRH or buserelin for 90 days. Serum PRL levels decreased significantly in the patients with microprolactinomas by 65%, from 156 ± 93 (± SD) to 54 ± 49 μg/L on day 90 (P = 0.011), but it did not decrease in the macroprolactinoma patients. Mean serum LH and FSH decreased by 43% and 62.5%, respectively, in all eight patients. There was no statistically significant correlation between the serum PRL and LH or FSH levels in the microprolactinoma patients. We conclude that LHRH agonists can counteract the hyperprolactinemia produced by microprolactinomas and that the effect probably is not exerted by an action on the gonadotrophs.
UR - http://www.scopus.com/inward/record.url?scp=0024344908&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024344908&partnerID=8YFLogxK
M3 - Article
C2 - 2526819
AN - SCOPUS:0024344908
VL - 69
SP - 444
EP - 447
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 2
ER -